Meeting
2022 ASCO Genitourinary Cancers Symposium
Randomized phase II study to assess the efficacy and tolerability of sunitinib by dose administration regimen in anti-angiogenic naïve patients with metastatic renal cell carcinoma (mRCC): Final analysis of SURF study.
Authors
Antoine Thiery-Vuillemin
Medical Oncology Department, CHRU Jean Minjoz, Besançon, France
Antoine Thiery-Vuillemin , Gwenaelle Gravis , Friederike Schlürmann , Emmanuelle Bompas , Frederic Rolland , Marine Gross-Goupil , Yann-Alexandre Vano , Aline Guillot , Philippe Barthélémy , Charlotte Joly , Mathieu Laramas , Louis-Marie Dourthe , Tristan Maurina , Hélène Gauthier , Kristell Taillandy , Aurelia Meurisse , Dewi Vernerey , Laurence Albiges
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral, and Testicular Cancers
Track
Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT02689167
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 344)
DOI
10.1200/JCO.2022.40.6_suppl.344
Abstract #
344
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2017 Genitourinary Cancers Symposium
A phase II study of alternative sunitinib scheduling in patients with metastatic renal cell carcinoma.
First Author: Eric Jonasch
Poster
2017 ASCO Annual Meeting
Phase II study of alternate sunitinib schedule in patients with metastatic renal cell carinoma.
First Author: Eric Jonasch
Poster
2015 ASCO Annual Meeting
Phase II study of individualized sunitinib as first-line therapy for metastatic renal cell cancer (mRCC).
First Author: Georg A. Bjarnason
Poster
2014 ASCO Annual Meeting
A phase II study of bevacizumab (Bev) and temsirolimus (Tem) in VEGF-refractory metastatic renal cell carcinoma (mRCC).
First Author: Kathleen Margaret Mahoney